Searched for
SEMAGLUTIDE TABLETS
Sun will require HC nod for Semaglutide tablet launchThe Delhi High Court has directed Sun Pharma Laboratories to seek its approval before launching semaglutide tablets, following Novo Nordisk...- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Dr Reddy’s pauses weight loss drug on quality fearsDr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the ...
- Torrent Pharma recalls select batches of Semalix injection after Dr. Reddy's noticeTorrent Pharmaceuticals is voluntarily recalling select batches of its Semalix semaglutide injection pens. This action follows a product re...
- Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concernsDr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...
- Dr Reddy's flags quality issue in semaglutide batches, delays commercial suppliesDr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batche...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Novo rebrands diabetes pill as Ozempic to tap blockbuster nameNovo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Future diabetes care seen leaning towards GLP-1 drugsThe diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy stand...
- Novo Nordisk gears up for December Ozempic launch in India, sources sayDanish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month. This move aims to capture a significa...
- Weight-loss therapy goes pill-to-shot with higher efficacy, convenienceSales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lill...
- Weight-loss drug Ozempic to debut in India soonNovo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...
- Weight is over! Pharma companies race to make weight-loss drug semaglutideIndian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic vers...
- New oral diabetes + obesity drug's India sales surge 100%India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...
- Anti-obesity drug market gaining traction in IndiaAccording to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...
- Novo Nordisk searches for tablet to replace insulin shotsThe company that reaped nearly 80% of its $16 billion sales from insulin products last year is hopeful for a regulatory approval for its fi...
Load More
